CSII · Cardiovascular Systems Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '20 | Q2 '20 | Q1 '20 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.45M | $59.67M | $59.13M | $56.22M | $58.37M | $64.17M | $60.54M | $68.33M | $64.49M | $60.21M |
| Cost of Revenue | $18.46M | $16.70M | $18.07M | $14.79M | $14.31M | $13.92M | $12.56M | $13.72M | $12.67M | $11.48M |
| Gross Profit | $42.99M | $42.98M | $41.06M | $41.43M | $44.06M | $50.25M | $47.98M | $54.62M | $51.82M | $48.73M |
| R&D | $9.53M | $9.06M | $8.87M | $9.05M | $10.02M | $9.60M | $9.05M | $10.79M | $10.77M | $7.24M |
| SG&A | $41.64M | $44.48M | $40.40M | $41.68M | $41.85M | $40.06M | $40.28M | $46.87M | $46.75M | $41.11M |
| Total Operating Expenses | $51.52M | $53.88M | $49.62M | $51.08M | $52.18M | $49.97M | $49.64M | $57.99M | $57.75M | $48.34M |
| D&A | - | $874.0K | - | - | $954.0K | - | $725.0K | - | $740.0K | - |
| Operating Income | ($8.53M) | ($10.90M) | ($8.56M) | ($9.65M) | ($8.12M) | $283.0K | ($1.66M) | ($3.37M) | ($5.93M) | $384.0K |
| Interest Expense | $404.0K | $406.0K | $409.0K | $408.0K | $410.0K | $412.0K | $499.0K | $500.0K | $472.0K | $422.0K |
| Income Tax | $49.0K | ($19.0K) | $63.0K | $63.0K | $136.0K | $63.0K | $63.0K | $44.0K | $38.0K | $33.0K |
| Net Income | ($7.89M) | ($10.63M) | ($8.97M) | ($9.66M) | ($8.62M) | ($56.0K) | ($2.08M) | ($3.40M) | ($5.78M) | $492.0K |
| EPS - Basic | ($0.20) | ($0.27) | ($0.23) | ($0.25) | - | $0.00 | ($0.05) | ($0.10) | ($0.17) | $0.01 |
| EPS - Diluted | ($0.20) | ($0.27) | ($0.23) | ($0.15) | - | - | ($0.08) | ($0.10) | - | $0.01 |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '20 | Q2 '20 | Q1 '20 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $59.84M | $62.85M | $66.42M | $66.95M | $66.86M | $71.07M | $92.67M | $185.46M | $58.94M | $74.24M |
| Accounts Receivable | $40.23M | $40.26M | $39.68M | $34.67M | $36.45M | $40.03M | $29.97M | $25.21M | $34.62M | $36.02M |
| Inventory | $41.19M | $37.94M | $34.57M | $32.85M | $33.13M | $32.31M | $29.15M | $27.71M | $19.49M | $18.06M |
| Accounts Payable | $17.09M | $16.76M | $14.38M | $13.60M | $12.91M | $14.06M | $13.42M | $11.54M | $13.11M | $11.19M |
| Current Assets | $221.96M | $231.08M | $241.85M | $245.31M | $263.14M | $284.67M | $285.43M | $287.69M | $161.94M | $180.07M |
| Total Assets | $311.51M | $312.04M | $322.68M | $323.99M | $332.27M | $352.57M | $341.72M | $339.52M | $217.06M | $218.58M |
| Current Liabilities | $36.76M | $37.16M | $39.95M | $46.42M | $43.04M | $54.65M | $45.70M | $44.51M | $46.90M | $42.34M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $72.12M | $69.89M | $73.20M | $70.49M | $69.08M | $81.61M | $73.32M | $70.73M | $74.99M | $70.63M |
| Stockholders' Equity | $239.39M | $242.15M | $249.48M | $253.50M | $263.19M | $270.96M | $268.40M | $268.79M | $142.07M | $147.94M |
| Retained Earnings | ($443.41M) | ($435.50M) | ($423.68M) | ($413.88M) | ($394.99M) | ($381.38M) | ($368.56M) | ($363.07M) | ($340.82M) | ($329.54M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '20 | Q2 '20 | Q1 '20 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($13.65M) | - | - | ($10.78M) | - | ($2.16M) | - | ($5.72M) | - |
| Investing Cash Flow | - | $11.34M | - | - | $11.61M | - | ($87.19M) | - | ($4.05M) | - |
| Financing Cash Flow | - | ($1.26M) | - | - | ($5.03M) | - | ($3.44M) | - | ($5.53M) | - |
| CapEx | - | $688.0K | - | - | $1.10M | - | $1.13M | - | $543.0K | - |
| Free Cash Flow | - | ($14.34M) | - | - | ($11.89M) | - | ($3.29M) | - | ($6.26M) | - |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '20 | Q2 '20 | Q1 '20 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 70.0% | 72.0% | 69.4% | 73.7% | 75.5% | 78.3% | 79.2% | 79.9% | 80.4% | 80.9% |
| Operating margin | -13.9% | -18.3% | -14.5% | -17.2% | -13.9% | 0.4% | -2.7% | -4.9% | -9.2% | 0.6% |
| EBITDA margin | - | -16.8% | - | - | -12.3% | - | -1.5% | - | -8.1% | - |
| Net margin | -12.8% | -17.8% | -15.2% | -17.2% | -14.8% | -0.1% | -3.4% | -5.0% | -9.0% | 0.8% |
| Free cash flow margin | - | -24.0% | - | - | -20.4% | - | -5.4% | - | -9.7% | - |
| FCF / Net income | - | 1.35 | - | - | 1.38 | - | 1.59 | - | 1.08 | - |
| R&D / Revenue | 15.5% | 15.2% | 15.0% | 16.1% | 17.2% | 15.0% | 15.0% | 15.8% | 16.7% | 12.0% |
| SG&A / Revenue | 67.8% | 74.5% | 68.3% | 74.1% | 71.7% | 62.4% | 66.5% | 68.6% | 72.5% | 68.3% |
| Effective tax rate | - | - | - | - | - | 900.0% | - | - | - | 6.3% |
| Return on assets | -2.5% | -3.4% | -2.8% | -3.0% | -2.6% | -0.0% | -0.6% | -1.0% | -2.7% | 0.2% |
| Return on equity | -3.3% | -4.4% | -3.6% | -3.8% | -3.3% | -0.0% | -0.8% | -1.3% | -4.1% | 0.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.04 | 6.22 | 6.05 | 5.28 | 6.11 | 5.21 | 6.25 | 6.46 | 3.45 | 4.25 |
| Quick ratio | 4.92 | 5.20 | 5.19 | 4.58 | 5.34 | 4.62 | 5.61 | 5.84 | 3.04 | 3.83 |
| Cash ratio | 1.63 | 1.69 | 1.66 | 1.44 | 1.55 | 1.30 | 2.03 | 4.17 | 1.26 | 1.75 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -21.1x | -26.9x | -20.9x | -23.6x | -19.8x | 0.7x | -3.3x | -6.7x | -12.6x | 0.9x |
| Equity multiplier | 1.30 | 1.29 | 1.29 | 1.28 | 1.26 | 1.30 | 1.27 | 1.26 | 1.53 | 1.48 |
| Liabilities / Assets | 0.23 | 0.22 | 0.23 | 0.22 | 0.21 | 0.23 | 0.21 | 0.21 | 0.35 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | 0.19 | 0.18 | 0.17 | 0.18 | 0.18 | 0.18 | 0.20 | 0.30 | 0.28 |
| Inventory turnover | 0.45 | 0.44 | 0.52 | 0.45 | 0.43 | 0.43 | 0.43 | 0.50 | 0.65 | 0.64 |
| Days sales outstanding | 239d | 246d | 245d | 225d | 228d | 228d | 181d | 135d | 196d | 218d |
| Days inventory outstanding | 814d | 829d | 698d | 811d | 845d | 847d | 847d | 737d | 561d | 574d |
| Days payable outstanding | 338d | 366d | 290d | 336d | 329d | 369d | 390d | 307d | 378d | 356d |
| Cash conversion cycle | 716d | 709d | 653d | 700d | 744d | 706d | 638d | 565d | 380d | 437d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 3.9% | 2.2% | -7.8% | - | - | -6.1% | -4.4% | 13.5% | 29.8% | - |
| Revenue CAGR (3y) | -3.5% | -2.6% | -0.6% | -3.9% | 5.5% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 4.7% | -2.5% | -18.3% | - | - | -8.0% | -6.2% | 12.1% | 13.4% | 13.0% |
| Operating income growth (YoY) | 0.4% | -34.3% | - | - | - | - | - | - | -99.9% | - |
| Net income growth (YoY) | 12.0% | -23.4% | -15912.5% | - | - | 98.4% | - | - | -100.1% | - |
| EPS growth (YoY) | 13.0% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -20.6% | - | - | - | - | - | - | -234.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.0% | -8.0% | -7.9% | - | - | 0.8% | 89.5% | 81.7% | 6.0% | 10.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-06-30.
Product / service
$236.22M totalPeripheral$156.01M · 66.0%
Coronary$80.21M · 34.0%
Geographic
$236.22M totalUS$219.84M · 93.1%
International$16.38M · 6.9%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Cardiovascular Systems Inc against the 5 most active filers in the same SIC group.